DUBLIN–(BUSINESS WIRE)–The “China Human Vaccine Industry Report, 2019-2025” report has been added to ResearchAndMarkets.com’s offering.
The report highlights the following:
- China’s human vaccine industry (environment, status quo, demand, market size, import and export, and competitive pattern);
- Chinese human vaccine market segments (demand, lot release volume and competitive pattern);
- 22 human vaccine companies (operation, vaccine business);
- Summary and forecast.
China has been the world’s biggest producer and consumer of human vaccines over four decades of planned vaccination, a program that has reduced the incidence of multiple vaccine-targeted infectious diseases to the lowest level.
Following the vaccine scandal of Changsheng Bio-technology Co., Ltd. in 2018, the Vaccine Administration Law of the People’s Republic of China was enacted at the Eleventh Meeting of the Standing Committee of the 13th National People’s Congress on June 29th, 2019. The Law which is due to take effect on December 1, 2019, will be a boon for better regulation on the whole vaccine market and sound development of the vaccine industry.
The National Institutes for Food and Drug Control approved supply of 276.6 million doses (37 kinds of vaccines) to the market from January to July 2019. Thereof, China National Biotech Group (including Chengdu Institute of Biological Products Co., Ltd., Shanghai Institute of Biological Products Co., Ltd., Lanzhou Institute of Biological Products Co., Ltd., Wuhan Institute of Biological Products Co., Ltd., Changchun Institute of Biological Products Co., Ltd. and Changchun Keygen Biological Products Co., Ltd.) boasted the largest lot release volume, or 43.4% of the total, staying far ahead of others as the bellwether in the Chinese vaccine industry.
In China, homemade vaccines lead the market, and the imported take a small share (lower than 5%), especially in the EPI vaccines market which is in the monopoly of local big-name brands. That it takes one year to five years for imported vaccines to acquire the Imported Drug License helps explain why there are just several imported vaccines such as pentavalent vaccine, 13/23-valent pneumococcal vaccine and HPV vaccine available on the Chinese vaccine market.
Chinese vaccine companies have broken the monopoly of their foreign peers on new vaccines like 13-valent pneumococcal vaccine and HPV vaccine, in their race to spend more on research and development. In current stage, Walvax Biotechnology’s 13-valent pneumococcal vaccine has been applied for GMP certificate and is expected to be the first approved homemade vaccine of such kind in China in 2019; Beijing Wantai Biological Pharmacy Enterprise’s 2-valent HPV vaccine which was applied for launch in November 2017, undergoes the quick review by National Medical Products Administration, and is expected to be the first approved homemade vaccine of such sort in China in 2019.
China’s vaccine market will have a rosy prospect. The growing demand for vaccines comes with a large population base, the aging of the population, more than 15 million newborns each year and the two-child policy. As people live a better life, they also demand more extra EPI vaccines.
Key Topics Covered
1. Overview of Vaccine Industry
1.1 Definition & Classification
1.2 Industry Chain
2. China Human Vaccine Industry
2.1 Operating Environment
2.1.1 International Market
2.1.2 Policy Environment
2.1.3 Biopharmaceutical Market
2.2 Status Quo
2.3 Market Demand
2.4 Circulation Channels
2.5 Market Size
2.6 Import & Export
2.6.1 Import
2.6.2 Export
2.6.3 Average Price
2.7 Competition Pattern
3. Human Vaccine Market Segments in China
3.1 Hepatitis B Vaccine
3.1.1 Demand
3.1.2 Lot Release Volume
3.1.3 Competition Pattern
3.2 Meningococcal Vaccine
3.2.1 Demand
3.2.2 Lot Release Volume
3.2.3 Competition Pattern
3.2.4 Development Prospects
3.3 Hepatitis A Vaccine
3.4 Influenza Vaccine
3.5 HIB Vaccine
3.6 Human Rabies Vaccine
3.7 Varicella Vaccine
3.8 Pneumococcal Vaccines
3.9 DTP Vaccine
3.10 Poliomyelitis Vaccine
3.11 Hepatitis E Vaccine
4. Major Human Vaccine Manufacturers in China
4.1 China National Biotech Group
4.1.1 Profile
4.1.2 National Vaccine & Serum Institute
4.1.3 Chengdu Institute of Biological Products Co. Ltd.
4.1.4 Shanghai Institute of Biological Products Co. Ltd.
4.1.5 Wuhan Institute of Biological Products Co. Ltd.
4.1.6 Lanzhou Institute of Biological Products Co. Ltd.
4.1.7 Changchun Institute of Biological Products Co. Ltd.
4.1.8 Changchun Keygen Biological Products Co. Ltd.
4.2 Beijing Wantai Biological Pharmacy Enterprise Co. Ltd.
4.3 Hualan Biological Engineering Inc.
4.4 Chongqing Zhifei Biological Products Co. Ltd.
4.5 Walvax Biotechnology Co. Ltd.
4.6 Liaoning Cheng Da Co. Ltd.
4.7 Shenzhen Kangtai Biological Products Co. Ltd.
4.8 Changsheng Bio-Technology Co. Ltd.
4.9 Olymvax Biopharmaceuticals Inc.
4.10 Sinovac Biotech Ltd.
4.11 Changchun BCHT Biotechnology Co. Ltd.
4.12 Zhejiang Tianyuan Bio-Pharmaceutical Co. Ltd.
4.13 Tibet Amy Biotech & Vaccine Group Co. Ltd.
4.14 NCPC GeneTech Biotechnology Development Co. Ltd.
4.15 Dalian Aleph Biomedical Co. Ltd.
4.16 Beijing Minhai Biotechnology Co. Ltd.
4.17 CanSino Biologics Inc.
4.18 Other Enterprises
4.18.1 Shenzhen Sanofi Pasteur Biological Products Co. Ltd.
4.18.2 Convac Biotechnology Co. Ltd.
4.18.3 Chengdu Kanghua Biological Products Co. Ltd.
4.18.4 Guangzhou Nuocheng Biological Products
4.18.5 CanSino Biologics Inc.
5. Summary and Forecast
5.1 Summary
5.2 Development Trends
5.2.1 Human Vaccine Industry is Increasingly Concentrated
5.2.2 Two-child Policy is in Favor of Human Vaccine Industry Growth
5.2.3 Faster Aging of Population Boosts Human Vaccine Industry
5.2.4 HPV Vaccine Has a Rosy Prospect and Is Expected to Be Localized
5.2.5 Homemade 13-valent Pneumococcal Conjugate Vaccine is Likely to be Launched
5.2.6 Local Companies Invest More Heavily in Research and Development of Vaccine Products Which are Becoming More Various
5.2.7 Demand for Extra EPI Vaccines Is Growing
For more information about this report visit https://www.researchandmarkets.com/r/d3nuu6
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900